IDH2
2 drugsIsocitrate Dehydrogenase 2
Predictive biomarker for patient selection in 3 indications
Understanding IDH2
What it means: IDH2 mutations (similar to IDH1) produce oncometabolites blocking differentiation. R140 and R172 are common mutation sites.
Why it matters: IDH2 inhibitor enasidenib induces differentiation responses in IDH2-mutant AML, even in relapsed/refractory disease.
Testing: Tested via NGS or PCR-based assays targeting R140 and R172 hotspots.
2
Approved Drugs
3
Indications
2
Companies
IDH2 is a precision-medicine biomarker linked to 2 FDA-approved targeted drugs from 2 companies, spanning 3 indications including Astrocytoma, Oligodendroglioma, Acute Myeloid Leukemia. Explore the targeted therapies, indications, testing methods, and companies developing IDH2 drugs below.
Search IDH2 Clinical Trials
Search recruiting trials on ClinicalTrials.gov